Pharmacokinetics Test 3 Set 1

Front 1

Lithium Monitoring why? (3)

Back 1

1)narrow therapeutic range
2)wide inter-patient variation
3)intra-individual variations

Front 2

Pharmacotherapy for bipolar disorder (5)

Back 2

1)Lithium is first line option for euphoric mania
2)divalproex for euphoric or mixed mania
3)lamotrigine for acute depressive episodes in bipolar
4)second generation antipsychotics (aripiprazole, risperidone, ziprasidone)
5)carbamazepine

Front 3

Results of using the slow release version of Lithium (4)

Back 3

1)decr ADR's (tremor, nausea)
2)incr compliance
3)better urine []ing ability
4)incr diarrhea

Front 4

TCA indications for monitoring (7)

Back 4

1)inadequate response to normal doses
2)replase of depression following a good response
3)serious ADR's
4)CV disease
5)admin of higher than normal doses
6)noncompliance/drug interactions suspected
7)old pt w/ cardiac/other illness

Front 5

TCA Withdrawal rxn (6)

Back 5

CHOLINERGIC OVERDRIVE:
1)hypersalivation
2)lacrimation
3)urination
4)diarrhea
5)poor sleep

Front 6

SSRI PK model?

Back 6

nonlinear

Front 7

Indications for monitoring SSRI's (5)

Back 7

1)compliance
2)nonresponders
3)rapid metabolizers
4)changing antidepressant therapy
5)adverse effects

Front 8

SSRI's withdrawal symptoms (5)

Back 8

MOA: adaptive changes in N-methyl D-aspartate receptor complex during long term use
a)fatigue
b)cramps
c)insomnia
d)flu like symptoms

Front 9

Optimal BZD for elderly (3)

Back 9

1)short half life
2)few biotransformations
3)no active metabolites

Front 10

ABSTINENCE syndrome of BZD's is seen w/ what type of BZD's (3)

Back 10

1)short half-life
2)long therapy
3)abrupt withdrawal

Front 11

Symptoms of ABSTINENCE syndrome (4)

Back 11

1)anxiety
2)agitation
3)restless
4)impaired memory

Front 12

How to avoid ABSTINENCE syndrome (3)

Back 12

1)taper dose by 25% per week
2)until 1-2mg equivalents of alprazolam
3)then decrease by 25% of remaining dose every week